Novan Inc

NASDAQ:NOVN   3:58:49 PM EDT
10.88
+0.03 (+0.28%)
Products, Regulatory, Earnings Announcements

Novan Reports Positive Topline Results From Pivotal Phase 3 Trial Of SB206 In Patients With Molluscum Contagiosum

Published: 06/11/2021 10:45 GMT
Novan Inc (NOVN) - Novan Reports Positive Topline Results From Pivotal Phase 3 Trial of Sb206 in Patients With Molluscum Contagiosum.
Novan Inc - Novan Intends to Submit New Drug Application ("nda") No Later Than Q3 of 2022.
Novan Inc - B-simple4 Achieves Statistical Significance for Primary Endpoint With P-value Less Than 0.0001.
Novan Inc - No Serious Adverse Events Related to Treatment With Sb206.
Revenue is expected to be $0.83 Million
Adjusted EPS is expected to be -$0.53

Next Quarter Revenue Guidance is expected to be $0.83 Million
Next Quarter EPS Guidance is expected to be -$0.46

More details on our Analysts Page.